• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    2/6/24 12:31:29 PM ET
    $AHG
    $APLM
    $BIOL
    $BRTX
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • InVivo Therapeutics Hldg (NASDAQ:NVIV) stock rose 306.0% to $0.9 during Tuesday's regular session. The company's market cap stands at $2.7 million.
    • Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 56.02% to $4.4. The company's market cap stands at $10.7 million.
    • Tenax Therapeutics (NASDAQ:TENX) stock increased by 41.62% to $12.35. The market value of their outstanding shares is at $3.6 million.
    • Equillium (NASDAQ:EQ) stock increased by 35.62% to $1.08. The company's market cap stands at $38.1 million.
    • Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 31.11% to $1.77. The market value of their outstanding shares is at $202.7 million.
    • Immunome (NASDAQ:IMNM) stock increased by 26.06% to $21.28. The company's market cap stands at $958.2 million.

    Losers

    • BioRestorative Therapies (NASDAQ:BRTX) stock decreased by 57.1% to $1.48 during Tuesday's regular session. The market value of their outstanding shares is at $6.9 million.
    • Akso Health Group (NASDAQ:AHG) stock fell 26.13% to $1.65. The company's market cap stands at $176.7 million.
    • Sagimet Biosciences (NASDAQ:SGMT) stock decreased by 25.99% to $6.75. The market value of their outstanding shares is at $215.2 million.
    • Biolase (NASDAQ:BIOL) stock fell 23.79% to $0.53. The company's market cap stands at $1.8 million.
    • NanoString Technologies (NASDAQ:NSTG) stock declined by 19.05% to $0.08. The company's market cap stands at $4.0 million.
    • Apollomics (NASDAQ:APLM) shares declined by 18.93% to $0.59. The market value of their outstanding shares is at $52.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $APLM
    $BIOL
    $BRTX

    CompanyDatePrice TargetRatingAnalyst
    Equillium Inc.
    $EQ
    3/13/2026$12.00Buy
    Roth Capital
    Karyopharm Therapeutics Inc.
    $KPTI
    3/10/2026$28.00Buy
    Rodman & Renshaw
    Equillium Inc.
    $EQ
    2/25/2026$5.00Buy
    Stifel
    Immunome Inc.
    $IMNM
    2/12/2026$40.00Buy
    H.C. Wainwright
    Karyopharm Therapeutics Inc.
    $KPTI
    2/5/2026Overweight
    Cantor Fitzgerald
    Sagimet Biosciences Inc.
    $SGMT
    2/3/2026$27.00Buy
    Guggenheim
    Sagimet Biosciences Inc.
    $SGMT
    1/28/2026$8.00Equal Weight
    Barclays
    Immunome Inc.
    $IMNM
    12/1/2025$36.00Buy
    Truist
    More analyst ratings

    $AHG
    $APLM
    $BIOL
    $BRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Equillium Announces $35 Million Financing with RA Capital Management

    Capital strengthens the advancement of EQ504 through key clinical milestones Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2029 LA JOLLA, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. ("Equillium" or the "Company") (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a definitive securities purchase agreement with RA Capital Management that will provide approximately $35 million in gross proceeds to Equillium. Pursuant to the terms of the securities purchase agreement, the Company will issue approximately

    3/13/26 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

    Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026 Secured global, exclusive license to TAPI's innovative forms of resmetirom active pharmaceutical ingredients (API) First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis China's National Medical Products Administration (NMPA) accepted Ascletis' New Drug Application (NDA) for denifanstat for the

    3/11/26 7:30:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress. "We are pleased to announce that we have recently achieved our randomization target

    3/10/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $APLM
    $BIOL
    $BRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bienaime Jean Jacques bought $43,670 worth of shares (2,000 units at $21.84), increasing direct ownership by 5% to 38,415 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    3/12/26 6:05:05 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $100,018 worth of shares (4,729 units at $21.15), increasing direct ownership by 0.72% to 665,254 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/30/25 6:47:24 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Siegall Clay B bought $149,053 worth of shares (7,278 units at $20.48) and gifted 200,000 shares, decreasing direct ownership by 23% to 660,525 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    12/22/25 7:38:54 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $APLM
    $BIOL
    $BRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Equillium with a new price target

    Roth Capital initiated coverage of Equillium with a rating of Buy and set a new price target of $12.00

    3/13/26 8:47:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Karyopharm Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $28.00

    3/10/26 8:41:07 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Equillium with a new price target

    Stifel initiated coverage of Equillium with a rating of Buy and set a new price target of $5.00

    2/25/26 7:52:10 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $APLM
    $BIOL
    $BRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bienaime Jean Jacques bought $43,670 worth of shares (2,000 units at $21.84), increasing direct ownership by 5% to 38,415 units (SEC Form 4)

    4 - Immunome Inc. (0001472012) (Issuer)

    3/12/26 6:05:05 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Sr. Vice President and COO Zedelmayer Christine exercised 185,937 shares at a strike of $0.76 and sold $328,104 worth of shares (185,937 units at $1.76) (SEC Form 4)

    4/A - Equillium, Inc. (0001746466) (Issuer)

    3/11/26 8:25:15 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sr. Vice President and COO Zedelmayer Christine exercised 152,361 shares at a strike of $0.79 and sold $362,438 worth of shares (181,219 units at $2.00), decreasing direct ownership by 32% to 62,586 units (SEC Form 4)

    4 - Equillium, Inc. (0001746466) (Issuer)

    3/11/26 8:11:26 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $APLM
    $BIOL
    $BRTX
    SEC Filings

    View All

    Equillium Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - Equillium, Inc. (0001746466) (Filer)

    3/13/26 8:15:19 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Sagimet Biosciences Inc.

    S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)

    3/11/26 8:00:06 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Sagimet Biosciences Inc.

    S-8 - Sagimet Biosciences Inc. (0001400118) (Filer)

    3/11/26 7:58:48 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $APLM
    $BIOL
    $BRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $APLM
    $BIOL
    $BRTX
    Financials

    Live finance-specific insights

    View All

    Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

    – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Total Revenue was $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $115 Million for Full Year 2025 – – Company Provides Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Feb. 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapie

    2/12/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    -- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to b

    2/5/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

    Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, with varegacestat delivering an objective response rate of 56% Varegacestat was generally well tolerated with a manageable safety profile New Drug Application submission to U.S. FDA planned for Q2 2026 Company to host conference call today at 8:30 a.m. ET Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacest

    12/15/25 7:00:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $APLM
    $BIOL
    $BRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immunome Inc.

    SC 13G/A - Immunome Inc. (0001472012) (Subject)

    11/14/24 9:00:58 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care